#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-5	Brain	_
1-2	6-19	morphological	_
1-3	20-23	and	_
1-4	24-34	functional	_
1-5	35-43	features	_
1-6	44-46	in	_
1-7	47-56	cognitive	_
1-8	57-66	subgroups	_
1-9	67-69	of	_
1-10	70-83	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-11	84-87	Aim	_
1-12	88-96	Previous	_
1-13	97-104	studies	_
1-14	105-109	have	_
1-15	110-118	reported	_
1-16	119-128	different	_
1-17	129-134	brain	_
1-18	135-147	morphologies	_
1-19	148-150	in	_
1-20	151-160	different	_
1-21	161-170	cognitive	_
1-22	171-180	subgroups	_
1-23	181-183	of	_
1-24	184-192	patients	_
1-25	193-197	with	_
1-26	198-211	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-27	212-213	.	_

2-1	214-216	We	_
2-2	217-222	aimed	_
2-3	223-225	to	_
2-4	226-233	examine	_
2-5	234-237	the	_
2-6	238-243	brain	_
2-7	244-254	structures	_
2-8	255-258	and	_
2-9	259-269	functional	_
2-10	270-282	connectivity	_
2-11	283-285	in	_
2-12	286-291	these	_
2-13	292-301	cognitive	_
2-14	302-311	subgroups	_
2-15	312-314	of	_
2-16	315-328	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-17	329-330	.	_

3-1	331-338	Methods	_
3-2	339-341	We	_
3-3	342-350	compared	_
3-4	351-356	brain	_
3-5	357-367	structures	_
3-6	368-373	among	_
3-7	374-381	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-8	382-390	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-9	391-394	and	_
3-10	395-406	cognitively	_
3-11	407-419	deteriorated	_
3-12	420-423	and	_
3-13	424-433	preserved	_
3-14	434-443	subgroups	_
3-15	444-446	of	_
3-16	447-455	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-17	456-460	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-18	461-474	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-19	475-484	according	_
3-20	485-487	to	_
3-21	488-491	the	_
3-22	492-499	decline	_
3-23	500-502	in	_
3-24	503-505	IQ	_
3-25	506-507	.	_

4-1	508-520	Connectivity	_
4-2	521-529	analyses	_
4-3	530-537	between	_
4-4	538-549	subcortical	_
4-5	550-557	regions	_
4-6	558-561	and	_
4-7	562-567	other	_
4-8	568-573	brain	_
4-9	574-579	areas	_
4-10	580-584	were	_
4-11	585-594	performed	_
4-12	595-600	using	_
4-13	601-614	resting‐state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-14	615-625	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-15	626-634	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-16	635-644	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-17	645-652	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-18	653-658	among	_
4-19	659-662	the	_
4-20	663-669	groups	_
4-21	670-671	.	_

5-1	672-679	Results	_
5-2	680-685	Whole	_
5-3	686-691	brain	_
5-4	692-695	and	_
5-5	696-701	total	_
5-6	702-710	cortical	_
5-7	711-715	gray	_
5-8	716-722	matter	_
5-9	723-724	,	_
5-10	725-730	right	_
5-11	731-739	fusiform	_
5-12	740-745	gyrus	_
5-13	746-747	,	_
5-14	748-752	left	_
5-15	753-757	pars	_
5-16	758-767	orbitalis	_
5-17	768-773	gyrus	_
5-18	774-775	,	_
5-19	776-781	right	_
5-20	782-786	pars	_
5-21	787-799	triangularis	_
5-22	800-801	,	_
5-23	802-806	left	_
5-24	807-815	superior	_
5-25	816-824	temporal	_
5-26	825-830	gyrus	_
5-27	831-834	and	_
5-28	835-839	left	_
5-29	840-846	insula	_
5-30	847-854	volumes	_
5-31	855-856	,	_
5-32	857-860	and	_
5-33	861-870	bilateral	_
5-34	871-879	cortical	_
5-35	880-889	thickness	_
5-36	890-894	were	_
5-37	895-904	decreased	_
5-38	905-907	in	_
5-39	908-911	the	_
5-40	912-924	deteriorated	_
5-41	925-930	group	_
5-42	931-939	compared	_
5-43	940-942	to	_
5-44	943-946	the	_
5-45	947-954	control	_
5-46	955-958	and	_
5-47	959-968	preserved	_
5-48	969-975	groups	_
5-49	976-977	.	_

6-1	978-982	Both	_
6-2	983-996	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-3	997-1006	subgroups	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-4	1007-1010	had	_
6-5	1011-1020	increased	_
6-6	1021-1025	left	_
6-7	1026-1033	lateral	_
6-8	1034-1043	ventricle	_
6-9	1044-1045	,	_
6-10	1046-1051	right	_
6-11	1052-1059	putamen	_
6-12	1060-1063	and	_
6-13	1064-1068	left	_
6-14	1069-1077	pallidum	_
6-15	1078-1079	,	_
6-16	1080-1083	and	_
6-17	1084-1093	decreased	_
6-18	1094-1103	bilateral	_
6-19	1104-1115	hippocampus	_
6-20	1116-1117	,	_
6-21	1118-1122	left	_
6-22	1123-1133	precentral	_
6-23	1134-1139	gyrus	_
6-24	1140-1141	,	_
6-25	1142-1147	right	_
6-26	1148-1155	rostral	_
6-27	1156-1162	middle	_
6-28	1163-1170	frontal	_
6-29	1171-1176	gyrus	_
6-30	1177-1178	,	_
6-31	1179-1182	and	_
6-32	1183-1192	bilateral	_
6-33	1193-1201	superior	_
6-34	1202-1209	frontal	_
6-35	1210-1215	gyrus	_
6-36	1216-1223	volumes	_
6-37	1224-1232	compared	_
6-38	1233-1237	with	_
6-39	1238-1246	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-40	1247-1248	.	_

7-1	1249-1266	Hyperconnectivity	_
7-2	1267-1274	between	_
7-3	1275-1278	the	_
7-4	1279-1287	thalamus	_
7-5	1288-1291	and	_
7-6	1292-1293	a	_
7-7	1294-1299	broad	_
7-8	1300-1305	range	_
7-9	1306-1308	of	_
7-10	1309-1314	brain	_
7-11	1315-1322	regions	_
7-12	1323-1326	was	_
7-13	1327-1335	observed	_
7-14	1336-1338	in	_
7-15	1339-1342	the	_
7-16	1343-1355	deteriorated	_
7-17	1356-1361	group	_
7-18	1362-1370	compared	_
7-19	1371-1373	to	_
7-20	1374-1386	connectivity	_
7-21	1387-1389	in	_
7-22	1390-1393	the	_
7-23	1394-1401	control	_
7-24	1402-1407	group	_
7-25	1408-1409	,	_
7-26	1410-1413	and	_
7-27	1414-1418	this	_
7-28	1419-1436	hyperconnectivity	_
7-29	1437-1440	was	_
7-30	1441-1445	less	_
7-31	1446-1453	evident	_
7-32	1454-1456	in	_
7-33	1457-1460	the	_
7-34	1461-1470	preserved	_
7-35	1471-1476	group	_
7-36	1477-1478	.	_

8-1	1479-1481	We	_
8-2	1482-1486	also	_
8-3	1487-1492	found	_
8-4	1493-1510	hyperconnectivity	_
8-5	1511-1518	between	_
8-6	1519-1522	the	_
8-7	1523-1532	accumbens	_
8-8	1533-1536	and	_
8-9	1537-1540	the	_
8-10	1541-1549	superior	_
8-11	1550-1553	and	_
8-12	1554-1560	middle	_
8-13	1561-1568	frontal	_
8-14	1569-1573	gyri	_
8-15	1574-1576	in	_
8-16	1577-1580	the	_
8-17	1581-1590	preserved	_
8-18	1591-1596	group	_
8-19	1597-1605	compared	_
8-20	1606-1610	with	_
8-21	1611-1623	connectivity	_
8-22	1624-1626	in	_
8-23	1627-1630	the	_
8-24	1631-1643	deteriorated	_
8-25	1644-1649	group	_
8-26	1650-1651	.	_

9-1	1652-1662	Conclusion	_
9-2	1663-1668	These	_
9-3	1669-1677	findings	_
9-4	1678-1685	provide	_
9-5	1686-1694	evidence	_
9-6	1695-1697	of	_
9-7	1698-1707	prominent	_
9-8	1708-1718	structural	_
9-9	1719-1722	and	_
9-10	1723-1733	functional	_
9-11	1734-1739	brain	_
9-12	1740-1753	abnormalities	_
9-13	1754-1756	in	_
9-14	1757-1769	deteriorated	http://maven.renci.org/NeuroBridge/neurobridge#Medicated
9-15	1770-1778	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-16	1779-1783	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-17	1784-1797	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-18	1798-1799	,	_
9-19	1800-1810	suggesting	_
9-20	1811-1815	that	_
9-21	1816-1825	cognitive	_
9-22	1826-1835	subgroups	_
9-23	1836-1838	in	_
9-24	1839-1852	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-25	1853-1858	might	_
9-26	1859-1861	be	_
9-27	1862-1868	useful	_
9-28	1869-1877	biotypes	_
9-29	1878-1880	to	_
9-30	1881-1890	elucidate	_
9-31	1891-1896	brain	_
9-32	1897-1912	pathophysiology	_
9-33	1913-1916	for	_
9-34	1917-1920	new	_
9-35	1921-1931	diagnostic	_
9-36	1932-1935	and	_
9-37	1936-1945	treatment	_
9-38	1946-1956	strategies	_
9-39	1957-1958	.	_

10-1	1959-1966	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
10-2	1967-1979	Participants	_
10-3	1980-1983	The	_
10-4	1984-1992	subjects	_
10-5	1993-2002	consisted	_
10-6	2003-2005	of	_
10-7	2006-2009	171	_
10-8	2010-2018	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-9	2019-2023	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-10	2024-2037	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-11	2038-2039	(	_
10-12	2040-2042	60	_
10-13	2043-2046	for	_
10-14	2047-2052	brain	_
10-15	2053-2065	connectivity	_
10-16	2066-2074	analysis	_
10-17	2075-2076	)	_
10-18	2077-2080	and	_
10-19	2081-2084	633	_
10-20	2085-2087	HC	_
10-21	2088-2089	(	_
10-22	2090-2093	234	_
10-23	2094-2097	for	_
10-24	2098-2103	brain	_
10-25	2104-2116	connectivity	_
10-26	2117-2125	analysis	_
10-27	2126-2127	)	_
10-28	2128-2129	.	_

11-1	2130-2140	Diagnostic	_
11-2	2141-2144	and	_
11-3	2145-2154	exclusion	_
11-4	2155-2163	criteria	_
11-5	2164-2168	have	_
11-6	2169-2173	been	_
11-7	2174-2183	described	_
11-8	2184-2197	previously.19	_
11-9	2198-2199	,	_
11-10	2200-2202	25	_
11-11	2203-2210	Written	_
11-12	2211-2219	informed	_
11-13	2220-2227	consent	_
11-14	2228-2231	was	_
11-15	2232-2240	obtained	_
11-16	2241-2245	from	_
11-17	2246-2249	all	_
11-18	2250-2258	subjects	_
11-19	2259-2264	after	_
11-20	2265-2268	the	_
11-21	2269-2279	procedures	_
11-22	2280-2283	had	_
11-23	2284-2288	been	_
11-24	2289-2294	fully	_
11-25	2295-2304	explained	_
11-26	2305-2306	.	_

12-1	2307-2310	The	_
12-2	2311-2316	study	_
12-3	2317-2320	was	_
12-4	2321-2330	performed	_
12-5	2331-2333	in	_
12-6	2334-2344	accordance	_
12-7	2345-2349	with	_
12-8	2350-2353	the	_
12-9	2354-2359	World	_
12-10	2360-2367	Medical	_
12-11	2368-2379	Association	_
12-12	2380-2382	's	_
12-13	2383-2394	Declaration	_
12-14	2395-2397	of	_
12-15	2398-2406	Helsinki	_
12-16	2407-2410	and	_
12-17	2411-2414	was	_
12-18	2415-2423	approved	_
12-19	2424-2426	by	_
12-20	2427-2430	the	_
12-21	2431-2439	Research	_
12-22	2440-2447	Ethical	_
12-23	2448-2457	Committee	_
12-24	2458-2460	of	_
12-25	2461-2466	Osaka	_
12-26	2467-2477	University	_
12-27	2478-2479	.	_

13-1	2480-2483	All	_
13-2	2484-2496	participants	_
13-3	2497-2505	provided	_
13-4	2506-2513	written	_
13-5	2514-2521	consent	_
13-6	2522-2524	to	_
13-7	2525-2528	the	_
13-8	2529-2534	study	_
13-9	2535-2540	after	_
13-10	2541-2545	full	_
13-11	2546-2557	explanation	_
13-12	2558-2560	of	_
13-13	2561-2564	the	_
13-14	2565-2570	study	_
13-15	2571-2581	procedures	_
13-16	2582-2583	.	_

14-1	2584-2593	Anonymity	_
14-2	2594-2597	was	_
14-3	2598-2607	preserved	_
14-4	2608-2611	for	_
14-5	2612-2615	all	_
14-6	2616-2628	participants	_
14-7	2629-2630	.	_

15-1	2631-2640	Cognitive	_
15-2	2641-2649	measures	_
15-3	2650-2653	and	_
15-4	2654-2659	other	_
15-5	2660-2668	measures	_
15-6	2669-2672	All	_
15-7	2673-2685	participants	_
15-8	2686-2690	were	_
15-9	2691-2703	administered	_
15-10	2704-2707	the	_
15-11	2708-2718	full‐scale	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
15-12	2719-2727	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-13	2728-2733	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-14	2734-2746	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-15	2747-2752	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-16	2753-2757	–III	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-17	2758-2759	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-18	2760-2768	WAIS‐III	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-19	2769-2770	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
15-20	2771-2773	26	_
15-21	2774-2776	to	_
15-22	2777-2783	obtain	_
15-23	2784-2789	their	_
15-24	2790-2797	current	_
15-25	2798-2800	IQ	_
15-26	2801-2804	and	_
15-27	2805-2808	the	_
15-28	2809-2817	Japanese	_
15-29	2818-2825	version	_
15-30	2826-2828	of	_
15-31	2829-2832	the	_
15-32	2833-2841	National	_
15-33	2842-2847	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
15-34	2848-2855	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
15-35	2856-2860	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
15-36	2861-2863	50	_
15-37	2864-2865	(	_
15-38	2866-2870	JART	_
15-39	2871-2872	)	_
15-40	2873-2875	27	_
15-41	2876-2878	to	_
15-42	2879-2885	obtain	_
15-43	2886-2888	an	_
15-44	2889-2898	estimated	_
15-45	2899-2908	premorbid	_
15-46	2909-2911	IQ	_
15-47	2912-2917	score	_
15-48	2918-2919	.	_

16-1	2920-2923	The	_
16-2	2924-2932	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#Revised
16-3	2933-2939	Memory	http://maven.renci.org/NeuroBridge/neurobridge#Revised
16-4	2940-2945	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Revised
16-5	2946-2947	–	http://maven.renci.org/NeuroBridge/neurobridge#Revised
16-6	2948-2957	Revised28	_
16-7	2958-2961	was	_
16-8	2962-2974	administered	_
16-9	2975-2977	to	_
16-10	2978-2984	assess	_
16-11	2985-2988	the	_
16-12	2989-2995	memory	_
16-13	2996-3007	functioning	_
16-14	3008-3010	of	_
16-15	3011-3014	the	_
16-16	3015-3027	participants	_
16-17	3028-3029	.	_

17-1	3030-3037	Current	_
17-2	3038-3046	symptoms	_
17-3	3047-3049	of	_
17-4	3050-3063	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-5	3064-3068	were	_
17-6	3069-3078	evaluated	_
17-7	3079-3084	using	_
17-8	3085-3088	the	_
17-9	3089-3097	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-10	3098-3101	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-11	3102-3110	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-12	3111-3119	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-13	3120-3125	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-14	3126-3127	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-15	3128-3133	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-16	3134-3135	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-17	3136-3139	.29	_
17-18	3140-3145	Daily	_
17-19	3146-3151	doses	_
17-20	3152-3154	of	_
17-21	3155-3169	antipsychotics	_
17-22	3170-3171	,	_
17-23	3172-3181	expressed	_
17-24	3182-3184	as	_
17-25	3185-3188	the	_
17-26	3189-3203	chlorpromazine	_
17-27	3204-3214	equivalent	_
17-28	3215-3216	(	_
17-29	3217-3222	CPZeq	_
17-30	3223-3224	)	_
17-31	3225-3226	,	_
17-32	3227-3229	in	_
17-33	3230-3238	patients	_
17-34	3239-3243	were	_
17-35	3244-3254	calculated	_
17-36	3255-3264	according	_
17-37	3265-3267	to	_
17-38	3268-3276	previous	_
17-39	3277-3290	literature.30	_
17-40	3291-3305	Classification	_
17-41	3306-3308	of	_
17-42	3309-3311	IQ	_
17-43	3312-3319	decline	_
17-44	3320-3329	subgroups	_
17-45	3330-3335	Based	_
17-46	3336-3338	on	_
17-47	3339-3347	previous	_
17-48	3348-3359	findings,22	_
17-49	3360-3362	we	_
17-50	3363-3373	classified	_
17-51	3374-3382	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-52	3383-3387	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-53	3388-3401	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-54	3402-3406	into	_
17-55	3407-3412	three	_
17-56	3413-3419	groups	_
17-57	3420-3421	:	_
17-58	3422-3423	(	_
17-59	3424-3425	i	_
17-60	3426-3427	)	_
17-61	3428-3440	deteriorated	_
17-62	3441-3442	,	_
17-63	3443-3448	those	_
17-64	3449-3459	displaying	_
17-65	3460-3461	a	_
17-66	3462-3472	meaningful	_
17-67	3473-3480	decline	_
17-68	3481-3483	in	_
17-69	3484-3486	IQ	_
17-70	3487-3488	(	_
17-71	3489-3492	≥10	_
17-72	3493-3499	points	_
17-73	3500-3501	)	_
17-74	3502-3504	as	_
17-75	3505-3514	evidenced	_
17-76	3515-3517	by	_
17-77	3518-3521	the	_
17-78	3522-3532	difference	_
17-79	3533-3540	between	_
17-80	3541-3548	current	_
17-81	3549-3551	IQ	_
17-82	3552-3553	(	_
17-83	3554-3559	based	_
17-84	3560-3562	on	_
17-85	3563-3566	the	_
17-86	3567-3577	full‐scale	_
17-87	3578-3580	IQ	_
17-88	3581-3586	score	_
17-89	3587-3589	of	_
17-90	3590-3593	the	_
17-91	3594-3602	WAIS‐III	_
17-92	3603-3604	)	_
17-93	3605-3608	and	_
17-94	3609-3618	estimated	_
17-95	3619-3628	premorbid	_
17-96	3629-3631	IQ	_
17-97	3632-3637	score	_
17-98	3638-3639	(	_
17-99	3640-3645	based	_
17-100	3646-3648	on	_
17-101	3649-3652	the	_
17-102	3653-3657	JART	_
17-103	3658-3663	score	_
17-104	3664-3665	)	_
17-105	3666-3667	;	_
17-106	3668-3669	(	_
17-107	3670-3672	ii	_
17-108	3673-3674	)	_
17-109	3675-3684	preserved	_
17-110	3685-3686	,	_
17-111	3687-3692	those	_
17-112	3693-3699	having	_
17-113	3700-3702	an	_
17-114	3703-3712	estimated	_
17-115	3713-3722	premorbid	_
17-116	3723-3725	IQ	_
17-117	3726-3731	score	_
17-118	3732-3737	above	_
17-119	3738-3740	90	_
17-120	3741-3744	and	_
17-121	3745-3749	less	_
17-122	3750-3754	than	_
17-123	3755-3756	a	_
17-124	3757-3765	10‐point	_
17-125	3766-3776	difference	_
17-126	3777-3784	between	_
17-127	3785-3790	their	_
17-128	3791-3800	estimated	_
17-129	3801-3810	premorbid	_
17-130	3811-3813	IQ	_
17-131	3814-3817	and	_
17-132	3818-3823	their	_
17-133	3824-3831	current	_
17-134	3832-3834	IQ	_
17-135	3835-3836	;	_
17-136	3837-3840	and	_
17-137	3841-3842	(	_
17-138	3843-3846	iii	_
17-139	3847-3848	)	_
17-140	3849-3860	compromised	_
17-141	3861-3862	,	_
17-142	3863-3868	those	_
17-143	3869-3879	displaying	_
17-144	3880-3882	an	_
17-145	3883-3892	estimated	_
17-146	3893-3902	premorbid	_
17-147	3903-3905	IQ	_
17-148	3906-3911	score	_
17-149	3912-3917	below	_
17-150	3918-3920	90	_
17-151	3921-3924	and	_
17-152	3925-3929	less	_
17-153	3930-3934	than	_
17-154	3935-3936	a	_
17-155	3937-3945	10‐point	_
17-156	3946-3956	difference	_
17-157	3957-3964	between	_
17-158	3965-3970	their	_
17-159	3971-3980	estimated	_
17-160	3981-3990	premorbid	_
17-161	3991-3993	IQ	_
17-162	3994-3997	and	_
17-163	3998-4003	their	_
17-164	4004-4011	current	_
17-165	4012-4014	IQ	_
17-166	4015-4016	.	_

18-1	4017-4020	The	_
18-2	4021-4030	existence	_
18-3	4031-4033	of	_
18-4	4034-4035	a	_
18-5	4036-4044	10‐point	_
18-6	4045-4047	IQ	_
18-7	4048-4055	decline	_
18-8	4056-4060	took	_
18-9	4061-4071	precedence	_
18-10	4072-4076	over	_
18-11	4077-4083	either	_
18-12	4084-4086	of	_
18-13	4087-4090	the	_
18-14	4091-4098	cut‐off	_
18-15	4099-4109	strategies	_
18-16	4110-4119	described	_
18-17	4120-4121	.	_

19-1	4122-4125	The	_
19-2	4126-4133	numbers	_
19-3	4134-4136	in	_
19-4	4137-4141	each	_
19-5	4142-4147	group	_
19-6	4148-4152	were	_
19-7	4153-4155	as	_
19-8	4156-4163	follows	_
19-9	4164-4165	:	_
19-10	4166-4178	deteriorated	_
19-11	4179-4180	,	_
19-12	4181-4182	n	_
19-13	4183-4184	=	_
19-14	4185-4188	111	_
19-15	4189-4190	(	_
19-16	4191-4193	65	_
19-17	4194-4195	%	_
19-18	4196-4197	)	_
19-19	4198-4199	;	_
19-20	4200-4209	preserved	_
19-21	4210-4211	,	_
19-22	4212-4213	n	_
19-23	4214-4215	=	_
19-24	4216-4218	54	_
19-25	4219-4220	(	_
19-26	4221-4223	32	_
19-27	4224-4225	%	_
19-28	4226-4227	)	_
19-29	4228-4229	;	_
19-30	4230-4233	and	_
19-31	4234-4245	compromised	_
19-32	4246-4247	,	_
19-33	4248-4249	n	_
19-34	4250-4251	=	_
19-35	4252-4253	6	_
19-36	4254-4255	(	_
19-37	4256-4257	4	_
19-38	4258-4259	%	_
19-39	4260-4261	)	_
19-40	4262-4263	(	_
19-41	4264-4267	Fig	_
19-42	4268-4269	.	_

20-1	4270-4272	S1	_
20-2	4273-4274	)	_
20-3	4275-4276	.	_

21-1	4277-4279	As	_
21-2	4280-4283	the	_
21-3	4284-4295	compromised	_
21-4	4296-4301	group	_
21-5	4302-4305	was	_
21-6	4306-4309	too	_
21-7	4310-4315	small	_
21-8	4316-4317	(	_
21-9	4318-4319	n	_
21-10	4320-4321	=	_
21-11	4322-4323	6	_
21-12	4324-4325	)	_
21-13	4326-4327	,	_
21-14	4328-4330	we	_
21-15	4331-4339	excluded	_
21-16	4340-4344	this	_
21-17	4345-4350	group	_
21-18	4351-4355	from	_
21-19	4356-4359	the	_
21-20	4360-4368	analysis	_
21-21	4369-4370	.	_

22-1	4371-4382	Statistical	_
22-2	4383-4391	analysis	_
22-3	4392-4395	for	_
22-4	4396-4408	demographics	_
22-5	4409-4412	and	_
22-6	4413-4421	clinical	_
22-7	4422-4437	characteristics	_
22-8	4438-4449	Statistical	_
22-9	4450-4458	analyses	_
22-10	4459-4463	were	_
22-11	4464-4473	performed	_
22-12	4474-4479	using	_
22-13	4480-4484	spss	_
22-14	4485-4488	for	_
22-15	4489-4496	Windows	_
22-16	4497-4504	Version	_
22-17	4505-4507	24	_
22-18	4508-4509	(	_
22-19	4510-4514	SPSS	_
22-20	4515-4520	Japan	_
22-21	4521-4525	Inc.	_
22-22	4526-4527	,	_
22-23	4528-4533	Tokyo	_
22-24	4534-4535	,	_
22-25	4536-4541	Japan	_
22-26	4542-4543	)	_
22-27	4544-4545	.	_

23-1	4546-4551	Group	_
23-2	4552-4563	comparisons	_
23-3	4564-4566	of	_
23-4	4567-4570	sex	_
23-5	4571-4575	were	_
23-6	4576-4585	performed	_
23-7	4586-4591	using	_
23-8	4592-4595	the	_
23-9	4596-4603	χ2‐test	_
23-10	4604-4605	.	_

24-1	4606-4608	We	_
24-2	4609-4618	performed	_
24-3	4619-4626	t‐tests	_
24-4	4627-4629	to	_
24-5	4630-4637	compare	_
24-6	4638-4646	clinical	_
24-7	4647-4662	characteristics	_
24-8	4663-4670	between	_
24-9	4671-4680	preserved	_
24-10	4681-4684	and	_
24-11	4685-4697	deteriorated	_
24-12	4698-4704	groups	_
24-13	4705-4706	,	_
24-14	4707-4710	and	_
24-15	4711-4719	analysis	_
24-16	4720-4722	of	_
24-17	4723-4731	variance	_
24-18	4732-4733	(	_
24-19	4734-4739	anova	_
24-20	4740-4741	)	_
24-21	4742-4745	was	_
24-22	4746-4754	employed	_
24-23	4755-4758	for	_
24-24	4759-4770	comparisons	_
24-25	4771-4773	of	_
24-26	4774-4784	continuous	_
24-27	4785-4794	variables	_
24-28	4795-4796	,	_
24-29	4797-4799	as	_
24-30	4800-4811	appropriate	_
24-31	4812-4813	.	_

25-1	4814-4817	For	_
25-2	4818-4826	defining	_
25-3	4827-4838	statistical	_
25-4	4839-4851	significance	_
25-5	4852-4853	,	_
25-6	4854-4856	we	_
25-7	4857-4860	set	_
25-8	4861-4864	the	_
25-9	4865-4869	type	_
25-10	4870-4871	I	_
25-11	4872-4877	error	_
25-12	4878-4882	rate	_
25-13	4883-4884	(	_
25-14	4885-4892	P‐value	_
25-15	4893-4894	)	_
25-16	4895-4897	at	_
25-17	4898-4902	0.05	_
25-18	4903-4904	.	_

26-1	4905-4910	Cohen	_
26-2	4911-4913	's	_
26-3	4914-4915	d	_
26-4	4916-4922	effect	_
26-5	4923-4928	sizes	_
26-6	4929-4933	were	_
26-7	4934-4944	calculated	_
26-8	4945-4949	from	_
26-9	4950-4953	the	_
26-10	4954-4961	overall	_
26-11	4962-4967	group	_
26-12	4968-4976	contrast	_
26-13	4977-4978	.	_

27-1	4979-4989	Structural	_
27-2	4990-4993	and	_
27-3	4994-5004	functional	_
27-4	5005-5012	imaging	_
27-5	5013-5016	and	_
27-6	5017-5027	volumetric	_
27-7	5028-5031	and	_
27-8	5032-5044	connectivity	_
27-9	5045-5055	processing	_
27-10	5056-5058	We	_
27-11	5059-5068	performed	_
27-12	5069-5077	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-13	5078-5087	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-14	5088-5095	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-15	5096-5097	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-16	5098-5101	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-17	5102-5103	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-18	5104-5107	and	_
27-19	5108-5116	obtained	_
27-20	5117-5128	T1‐weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
27-21	5129-5135	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
27-22	5136-5140	with	_
27-23	5141-5144	two	_
27-24	5145-5154	different	_
27-25	5155-5163	scanners	_
27-26	5164-5165	:	_
27-27	5166-5171	Osaka	_
27-28	5172-5173	A	_
27-29	5174-5177	and	_
27-30	5178-5183	Osaka	_
27-31	5184-5185	B	_
27-32	5186-5187	.	_

28-1	5188-5190	We	_
28-2	5191-5198	scanned	_
28-3	5199-5202	109	_
28-4	5203-5211	patients	_
28-5	5212-5213	(	_
28-6	5214-5226	deteriorated	_
28-7	5227-5228	,	_
28-8	5229-5230	n	_
28-9	5231-5232	=	_
28-10	5233-5235	70	_
28-11	5236-5237	;	_
28-12	5238-5247	preserved	_
28-13	5248-5249	,	_
28-14	5250-5251	n	_
28-15	5252-5253	=	_
28-16	5254-5256	34	_
28-17	5257-5258	;	_
28-18	5259-5262	and	_
28-19	5263-5274	compromised	_
28-20	5275-5276	,	_
28-21	5277-5278	n	_
28-22	5279-5280	=	_
28-23	5281-5282	5	_
28-24	5283-5284	)	_
28-25	5285-5288	and	_
28-26	5289-5292	399	_
28-27	5293-5295	HC	_
28-28	5296-5300	with	_
28-29	5301-5306	Osaka	_
28-30	5307-5308	A	_
28-31	5309-5310	;	_
28-32	5311-5314	and	_
28-33	5315-5317	62	_
28-34	5318-5326	patients	_
28-35	5327-5328	(	_
28-36	5329-5341	deteriorated	_
28-37	5342-5343	,	_
28-38	5344-5345	n	_
28-39	5346-5347	=	_
28-40	5348-5350	41	_
28-41	5351-5352	;	_
28-42	5353-5362	preserved	_
28-43	5363-5364	,	_
28-44	5365-5366	n	_
28-45	5367-5368	=	_
28-46	5369-5371	20	_
28-47	5372-5373	;	_
28-48	5374-5377	and	_
28-49	5378-5389	compromised	_
28-50	5390-5391	,	_
28-51	5392-5393	n	_
28-52	5394-5395	=	_
28-53	5396-5397	1	_
28-54	5398-5399	)	_
28-55	5400-5403	and	_
28-56	5404-5407	234	_
28-57	5408-5410	HC	_
28-58	5411-5415	with	_
28-59	5416-5421	Osaka	_
28-60	5422-5423	B	_
28-61	5424-5425	.	_

29-1	5426-5429	The	_
29-2	5430-5437	scanner	_
29-3	5438-5442	type	_
29-4	5443-5446	for	_
29-5	5447-5452	Osaka	_
29-6	5453-5454	A	_
29-7	5455-5458	was	_
29-8	5459-5460	a	_
29-9	5461-5463	GE	_
29-10	5464-5467	1.5	_
29-11	5468-5469	T	_
29-12	5470-5471	,	_
29-13	5472-5477	Signa	_
29-14	5478-5484	EXCITE	_
29-15	5485-5486	.	_

30-1	5487-5498	T1‐weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-2	5499-5505	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-3	5506-5507	,	_
30-4	5508-5513	using	_
30-5	5514-5515	a	_
30-6	5516-5528	fast‐spoiled	_
30-7	5529-5537	gradient	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
30-8	5538-5542	echo	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
30-9	5543-5544	(	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
30-10	5545-5549	SPGR	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
30-11	5550-5551	)	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
30-12	5552-5555	and	_
30-13	5556-5557	a	_
30-14	5558-5562	head	_
30-15	5563-5565	QD	_
30-16	5566-5570	coil	_
30-17	5571-5572	,	_
30-18	5573-5577	were	_
30-19	5578-5586	acquired	_
30-20	5587-5591	with	_
30-21	5592-5595	the	_
30-22	5596-5605	following	_
30-23	5606-5616	parameters	_
30-24	5617-5618	:	_
30-25	5619-5629	repetition	_
30-26	5630-5634	time	_
30-27	5635-5636	(	_
30-28	5637-5639	TR	_
30-29	5640-5641	)	_
30-30	5642-5643	=	_
30-31	5644-5648	12.6	_
30-32	5649-5651	ms	_
30-33	5652-5653	,	_
30-34	5654-5658	echo	_
30-35	5659-5663	time	_
30-36	5664-5665	(	_
30-37	5666-5668	TE	_
30-38	5669-5670	)	_
30-39	5671-5672	=	_
30-40	5673-5676	4.2	_
30-41	5677-5679	ms	_
30-42	5680-5681	,	_
30-43	5682-5691	inversion	_
30-44	5692-5696	time	_
30-45	5697-5698	(	_
30-46	5699-5701	TI	_
30-47	5702-5703	)	_
30-48	5704-5705	=	_
30-49	5706-5709	400	_
30-50	5710-5712	ms	_
30-51	5713-5714	,	_
30-52	5715-5719	flip	_
30-53	5720-5725	angle	_
30-54	5726-5727	=	_
30-55	5728-5730	15	_
30-56	5731-5738	degrees	_
30-57	5739-5740	,	_
30-58	5741-5747	matrix	_
30-59	5748-5749	=	_
30-60	5750-5753	256	_
30-61	5754-5755	×	_
30-62	5756-5759	256	_
30-63	5760-5761	×	_
30-64	5762-5765	124	_
30-65	5766-5767	,	_
30-66	5768-5773	field	_
30-67	5774-5776	of	_
30-68	5777-5781	view	_
30-69	5782-5783	(	_
30-70	5784-5787	FOV	_
30-71	5788-5789	)	_
30-72	5790-5791	=	_
30-73	5792-5795	240	_
30-74	5796-5797	×	_
30-75	5798-5801	240	_
30-76	5802-5803	×	_
30-77	5804-5807	172	_
30-78	5808-5810	mm	_
30-79	5811-5812	,	_
30-80	5813-5818	voxel	_
30-81	5819-5823	size	_
30-82	5824-5825	=	_
30-83	5826-5832	0.9375	_
30-84	5833-5834	×	_
30-85	5835-5841	0.9375	_
30-86	5842-5843	×	_
30-87	5844-5847	1.4	_
30-88	5848-5850	mm	_
30-89	5851-5852	,	_
30-90	5853-5858	slice	_
30-91	5859-5868	thickness	_
30-92	5869-5870	=	_
30-93	5871-5874	1.4	_
30-94	5875-5877	mm	_
30-95	5878-5879	,	_
30-96	5880-5883	and	_
30-97	5884-5890	number	_
30-98	5891-5893	of	_
30-99	5894-5900	slices	_
30-100	5901-5902	=	_
30-101	5903-5906	124	_
30-102	5907-5908	.	_

31-1	5909-5912	The	_
31-2	5913-5918	slice	_
31-3	5919-5930	orientation	_
31-4	5931-5934	was	_
31-5	5935-5937	in	_
31-6	5938-5941	the	_
31-7	5942-5950	sagittal	_
31-8	5951-5956	plane	_
31-9	5957-5958	.	_

32-1	5959-5962	The	_
32-2	5963-5970	scanner	_
32-3	5971-5975	type	_
32-4	5976-5979	for	_
32-5	5980-5985	Osaka	_
32-6	5986-5987	B	_
32-7	5988-5991	was	_
32-8	5992-5993	a	_
32-9	5994-5996	GE	_
32-10	5997-6000	3.0	_
32-11	6001-6002	T	_
32-12	6003-6004	,	_
32-13	6005-6010	Signa	_
32-14	6011-6015	HDxt	_
32-15	6016-6017	.	_

33-1	6018-6029	T1‐weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-2	6030-6036	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-3	6037-6038	,	_
33-4	6039-6044	using	_
33-5	6045-6046	a	_
33-6	6047-6051	fast	_
33-7	6052-6056	SPGR	_
33-8	6057-6060	and	_
33-9	6061-6063	an	_
33-10	6064-6072	8HRBRAIN	_
33-11	6073-6077	coil	_
33-12	6078-6079	,	_
33-13	6080-6084	were	_
33-14	6085-6093	acquired	_
33-15	6094-6098	with	_
33-16	6099-6102	the	_
33-17	6103-6112	following	_
33-18	6113-6123	parameters	_
33-19	6124-6125	:	_
33-20	6126-6128	TR	_
33-21	6129-6130	=	_
33-22	6131-6134	7.2	_
33-23	6135-6137	ms	_
33-24	6138-6139	,	_
33-25	6140-6142	TE	_
33-26	6143-6144	=	_
33-27	6145-6148	2.9	_
33-28	6149-6151	ms	_
33-29	6152-6153	,	_
33-30	6154-6156	TI	_
33-31	6157-6158	=	_
33-32	6159-6162	400	_
33-33	6163-6165	ms	_
33-34	6166-6167	,	_
33-35	6168-6172	flip	_
33-36	6173-6178	angle	_
33-37	6179-6180	=	_
33-38	6181-6183	11	_
33-39	6184-6191	degrees	_
33-40	6192-6193	,	_
33-41	6194-6200	matrix	_
33-42	6201-6202	=	_
33-43	6203-6206	256	_
33-44	6207-6208	×	_
33-45	6209-6212	256	_
33-46	6213-6214	×	_
33-47	6215-6218	172	_
33-48	6219-6220	,	_
33-49	6221-6224	FOV	_
33-50	6225-6226	=	_
33-51	6227-6230	240	_
33-52	6231-6232	×	_
33-53	6233-6236	240	_
33-54	6237-6238	×	_
33-55	6239-6242	172	_
33-56	6243-6245	mm	_
33-57	6246-6247	,	_
33-58	6248-6253	voxel	_
33-59	6254-6258	size	_
33-60	6259-6260	=	_
33-61	6261-6267	0.9375	_
33-62	6268-6269	×	_
33-63	6270-6276	0.9375	_
33-64	6277-6278	×	_
33-65	6279-6280	1	_
33-66	6281-6283	mm	_
33-67	6284-6285	,	_
33-68	6286-6291	slice	_
33-69	6292-6301	thickness	_
33-70	6302-6303	=	_
33-71	6304-6305	1	_
33-72	6306-6308	mm	_
33-73	6309-6310	,	_
33-74	6311-6314	and	_
33-75	6315-6321	number	_
33-76	6322-6324	of	_
33-77	6325-6331	slices	_
33-78	6332-6333	=	_
33-79	6334-6337	172	_
33-80	6338-6339	.	_

34-1	6340-6343	The	_
34-2	6344-6349	slice	_
34-3	6350-6361	orientation	_
34-4	6362-6365	was	_
34-5	6366-6368	in	_
34-6	6369-6372	the	_
34-7	6373-6381	sagittal	_
34-8	6382-6387	plane	_
34-9	6388-6389	.	_

35-1	6390-6392	We	_
35-2	6393-6402	performed	_
35-3	6403-6413	structural	_
35-4	6414-6419	image	_
35-5	6420-6430	processing	_
35-6	6431-6433	in	_
35-7	6434-6437	the	_
35-8	6438-6442	same	_
35-9	6443-6446	way	_
35-10	6447-6449	as	_
35-11	6450-6454	that	_
35-12	6455-6464	performed	_
35-13	6465-6467	in	_
35-14	6468-6471	our	_
35-15	6472-6480	previous	_
35-16	6481-6489	study.17	_
35-17	6490-6491	,	_
35-18	6492-6494	18	_
35-19	6495-6496	,	_
35-20	6497-6499	19	_
35-21	6500-6502	We	_
35-22	6503-6510	checked	_
35-23	6511-6519	original	_
35-24	6520-6531	T1‐weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-25	6532-6538	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-26	6539-6546	through	_
35-27	6547-6553	visual	_
35-28	6554-6564	inspection	_
35-29	6565-6568	for	_
35-30	6569-6576	quality	_
35-31	6577-6584	control	_
35-32	6585-6586	.	_

36-1	6587-6589	We	_
36-2	6590-6598	excluded	_
36-3	6599-6605	images	_
36-4	6606-6610	with	_
36-5	6611-6612	a	_
36-6	6613-6616	low	_
36-7	6617-6632	signal‐to‐noise	_
36-8	6633-6638	ratio	_
36-9	6639-6641	or	_
36-10	6642-6645	any	_
36-11	6646-6655	artifacts	_
36-12	6656-6657	,	_
36-13	6658-6663	those	_
36-14	6664-6668	with	_
36-15	6669-6676	partial	_
36-16	6677-6685	deficits	_
36-17	6686-6687	,	_
36-18	6688-6691	and	_
36-19	6692-6697	those	_
36-20	6698-6702	with	_
36-21	6703-6706	any	_
36-22	6707-6715	abnormal	_
36-23	6716-6723	organic	_
36-24	6724-6732	findings	_
36-25	6733-6734	.	_

37-1	6735-6739	Next	_
37-2	6740-6741	,	_
37-3	6742-6744	we	_
37-4	6745-6754	processed	_
37-5	6755-6766	T1‐weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-6	6767-6774	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-7	6775-6779	data	_
37-8	6780-6784	that	_
37-9	6785-6788	had	_
37-10	6789-6795	passed	_
37-11	6796-6799	the	_
37-12	6800-6805	first	_
37-13	6806-6821	quality‐control	_
37-14	6822-6826	step	_
37-15	6827-6831	with	_
37-16	6832-6842	FreeSurfer	_
37-17	6843-6851	software	_
37-18	6852-6859	version	_
37-19	6860-6863	5.3	_
37-20	6864-6865	(	_
37-21	6866-6870	http	_
37-22	6871-6872	:	_
37-23	6873-6901	//surfer.nmr.mgh.harvard.edu	_
37-24	6902-6903	)	_
37-25	6904-6907	.30	_
37-26	6908-6915	Through	_
37-27	6916-6920	this	_
37-28	6921-6930	procedure	_
37-29	6931-6932	,	_
37-30	6933-6935	we	_
37-31	6936-6944	obtained	_
37-32	6945-6951	images	_
37-33	6952-6959	showing	_
37-34	6960-6963	the	_
37-35	6964-6975	subcortical	_
37-36	6976-6988	segmentation	_
37-37	6989-6992	and	_
37-38	6993-7001	regional	_
37-39	7002-7009	volumes	_
37-40	7010-7011	(	_
37-41	7012-7015	for	_
37-42	7016-7019	the	_
37-43	7020-7031	hippocampus	_
37-44	7032-7033	,	_
37-45	7034-7042	amygdala	_
37-46	7043-7044	,	_
37-47	7045-7053	thalamus	_
37-48	7054-7055	,	_
37-49	7056-7063	nucleus	_
37-50	7064-7073	accumbens	_
37-51	7074-7075	,	_
37-52	7076-7083	caudate	_
37-53	7084-7085	,	_
37-54	7086-7093	putamen	_
37-55	7094-7095	,	_
37-56	7096-7102	globus	_
37-57	7103-7111	pallidus	_
37-58	7112-7114	in	_
37-59	7115-7119	both	_
37-60	7120-7131	hemispheres	_
37-61	7132-7133	,	_
37-62	7134-7137	and	_
37-63	7138-7141	the	_
37-64	7142-7154	intracranial	_
37-65	7155-7161	volume	_
37-66	7162-7163	[	_
37-67	7164-7167	ICV	_
37-68	7168-7169	]	_
37-69	7170-7171	)	_
37-70	7172-7173	.	_

38-1	7174-7179	After	_
38-2	7180-7184	that	_
38-3	7185-7186	,	_
38-4	7187-7190	two	_
38-5	7191-7202	independent	_
38-6	7203-7214	researchers	_
38-7	7215-7223	visually	_
38-8	7224-7233	inspected	_
38-9	7234-7238	each	_
38-10	7239-7251	segmentation	_
38-11	7252-7257	image	_
38-12	7258-7260	to	_
38-13	7261-7268	exclude	_
38-14	7269-7275	images	_
38-15	7276-7280	with	_
38-16	7281-7285	poor	_
38-17	7286-7298	segmentation	_
38-18	7299-7300	.	_

39-1	7301-7303	No	_
39-2	7304-7311	subject	_
39-3	7312-7315	was	_
39-4	7316-7324	excluded	_
39-5	7325-7328	due	_
39-6	7329-7331	to	_
39-7	7332-7335	the	_
39-8	7336-7343	failure	_
39-9	7344-7346	of	_
39-10	7347-7357	FreeSurfer	_
39-11	7358-7368	processing	_
39-12	7369-7370	.	_

40-1	7371-7376	After	_
40-2	7377-7382	these	_
40-3	7383-7386	two	_
40-4	7387-7402	quality‐control	_
40-5	7403-7408	steps	_
40-6	7409-7410	,	_
40-7	7411-7413	we	_
40-8	7414-7422	obtained	_
40-9	7423-7426	the	_
40-10	7427-7430	raw	_
40-11	7431-7442	subcortical	_
40-12	7443-7449	volume	_
40-13	7450-7454	data	_
40-14	7455-7456	.	_

41-1	7457-7460	The	_
41-2	7461-7471	analytical	_
41-3	7472-7479	methods	_
41-4	7480-7484	used	_
41-5	7485-7487	in	_
41-6	7488-7491	the	_
41-7	7492-7497	study	_
41-8	7498-7500	by	_
41-9	7501-7504	van	_
41-10	7505-7508	Erp	_
41-11	7509-7511	et	_
41-12	7512-7517	al.16	_
41-13	7518-7522	from	_
41-14	7523-7532	ENIGMA‐SZ	_
41-15	7533-7537	were	_
41-16	7538-7546	followed	_
41-17	7547-7549	in	_
41-18	7550-7554	this	_
41-19	7555-7563	analysis	_
41-20	7564-7565	.	_

42-1	7566-7568	We	_
42-2	7569-7577	employed	_
42-3	7578-7581	the	_
42-4	7582-7592	normalized	_
42-5	7593-7601	regional	_
42-6	7602-7608	volume	_
42-7	7609-7611	to	_
42-8	7612-7618	remove	_
42-9	7619-7622	the	_
42-10	7623-7630	effects	_
42-11	7631-7633	of	_
42-12	7634-7637	the	_
42-13	7638-7649	confounding	_
42-14	7650-7657	factors	_
42-15	7658-7669	considering	_
42-16	7670-7676	linear	_
42-17	7677-7680	and	_
42-18	7681-7690	nonlinear	_
42-19	7691-7694	age	_
42-20	7695-7702	effects	_
42-21	7703-7705	on	_
42-22	7706-7717	subcortical	_
42-23	7718-7726	regional	_
42-24	7727-7734	volumes	_
42-25	7735-7737	as	_
42-26	7738-7747	described	_
42-27	7748-7761	previously.17	_
42-28	7762-7763	,	_
42-29	7764-7766	18	_
42-30	7767-7768	,	_
42-31	7769-7771	19	_
42-32	7772-7774	We	_
42-33	7775-7779	also	_
42-34	7780-7789	extracted	_
42-35	7790-7798	cortical	_
42-36	7799-7808	thickness	_
42-37	7809-7817	measures	_
42-38	7818-7822	from	_
42-39	7823-7827	both	_
42-40	7828-7836	scanners	_
42-41	7837-7842	using	_
42-42	7843-7853	Freesurfer	_
42-43	7854-7857	5.3	_
42-44	7858-7859	(	_
42-45	7860-7864	http	_
42-46	7865-7866	:	_
42-47	7867-7895	//surfer.nmr.mgh.harvard.edu	_
42-48	7896-7897	)	_
42-49	7898-7899	.	_

43-1	7900-7908	Cortical	_
43-2	7909-7922	parcellations	_
43-3	7923-7927	were	_
43-4	7928-7935	created	_
43-5	7936-7941	based	_
43-6	7942-7944	on	_
43-7	7945-7948	the	_
43-8	7949-7965	Desikan–Killiany	_
43-9	7966-7971	atlas	_
43-10	7972-7973	,	_
43-11	7974-7978	with	_
43-12	7979-7980	a	_
43-13	7981-7986	total	_
43-14	7987-7989	of	_
43-15	7990-7992	68	_
43-16	7993-7994	(	_
43-17	7995-7997	34	_
43-18	7998-8002	left	_
43-19	8003-8006	and	_
43-20	8007-8009	34	_
43-21	8010-8015	right	_
43-22	8016-8017	)	_
43-23	8018-8026	cortical	_
43-24	8027-8031	gray	_
43-25	8032-8038	matter	_
43-26	8039-8046	regions	_
43-27	8047-8048	.	_

44-1	8049-8060	Hemispheric	_
44-2	8061-8068	average	_
44-3	8069-8077	cortical	_
44-4	8078-8089	thicknesses	_
44-5	8090-8094	were	_
44-6	8095-8099	also	_
44-7	8100-8110	calculated	_
44-8	8111-8112	.	_

45-1	8113-8118	Based	_
45-2	8119-8121	on	_
45-3	8122-8125	the	_
45-4	8126-8138	standardized	_
45-5	8139-8145	ENIGMA	_
45-6	8146-8155	protocols	_
45-7	8156-8157	(	_
45-8	8158-8162	http	_
45-9	8163-8164	:	_
45-10	8165-8213	//enigma.ini.usc.edu/protocols/imaging-protocols	_
45-11	8214-8215	)	_
45-12	8216-8217	,	_
45-13	8218-8221	the	_
45-14	8222-8235	segmentations	_
45-15	8236-8240	were	_
45-16	8241-8249	visually	_
45-17	8250-8259	inspected	_
45-18	8260-8262	by	_
45-19	8263-8268	three	_
45-20	8269-8280	independent	_
45-21	8281-8292	researchers	_
45-22	8293-8296	and	_
45-23	8297-8310	statistically	_
45-24	8311-8320	evaluated	_
45-25	8321-8324	for	_
45-26	8325-8333	outliers	_
45-27	8334-8335	.	_

46-1	8336-8339	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
46-2	8340-8348	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
46-3	8349-8352	for	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
46-4	8353-8366	resting‐state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
46-5	8367-8371	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
46-6	8372-8373	(	_
46-7	8374-8381	rs‐fMRI	_
46-8	8382-8383	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
46-9	8384-8387	was	_
46-10	8388-8397	performed	_
46-11	8398-8400	on	_
46-12	8401-8406	Osaka	_
46-13	8407-8408	B	_
46-14	8409-8410	,	_
46-15	8411-8412	a	_
46-16	8413-8415	GE	_
46-17	8416-8420	3.0T	_
46-18	8421-8426	Signa	_
46-19	8427-8431	HDxt	_
46-20	8432-8437	using	_
46-21	8438-8440	an	_
46-22	8441-8449	8HRBRAIN	_
46-23	8450-8454	head	_
46-24	8455-8459	coil	_
46-25	8460-8461	.	_

47-1	8462-8468	RsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
47-2	8469-8472	was	_
47-3	8473-8481	acquired	_
47-4	8482-8487	using	_
47-5	8488-8489	a	_
47-6	8490-8492	T2	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-7	8493-8494	*	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-8	8495-8506	echo‐planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-9	8507-8514	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-10	8515-8516	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-11	8517-8520	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-12	8521-8522	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-13	8523-8531	sequence	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-14	8532-8536	with	_
47-15	8537-8540	the	_
47-16	8541-8550	following	_
47-17	8551-8561	parameters	_
47-18	8562-8563	:	_
47-19	8564-8569	TR/TE	_
47-20	8570-8571	,	_
47-21	8572-8576	2000	_
47-22	8577-8582	ms/30	_
47-23	8583-8585	ms	_
47-24	8586-8587	;	_
47-25	8588-8592	flip	_
47-26	8593-8598	angle	_
47-27	8599-8600	,	_
47-28	8601-8604	90°	_
47-29	8605-8606	;	_
47-30	8607-8618	acquisition	_
47-31	8619-8625	matrix	_
47-32	8626-8627	,	_
47-33	8628-8630	64	_
47-34	8631-8632	×	_
47-35	8633-8635	64	_
47-36	8636-8637	;	_
47-37	8638-8641	FOV	_
47-38	8642-8643	,	_
47-39	8644-8647	220	_
47-40	8648-8650	mm	_
47-41	8651-8652	×	_
47-42	8653-8656	220	_
47-43	8657-8659	mm	_
47-44	8660-8661	;	_
47-45	8662-8667	voxel	_
47-46	8668-8672	size	_
47-47	8673-8674	,	_
47-48	8675-8679	3.44	_
47-49	8680-8682	mm	_
47-50	8683-8684	×	_
47-51	8685-8689	3.44	_
47-52	8690-8692	mm	_
47-53	8693-8694	×	_
47-54	8695-8699	3.50	_
47-55	8700-8702	mm	_
47-56	8703-8704	;	_
47-57	8705-8710	slice	_
47-58	8711-8720	thickness	_
47-59	8721-8722	,	_
47-60	8723-8727	3.50	_
47-61	8728-8730	mm	_
47-62	8731-8732	;	_
47-63	8733-8736	and	_
47-64	8737-8742	slice	_
47-65	8743-8746	gap	_
47-66	8747-8748	,	_
47-67	8749-8753	none	_
47-68	8754-8755	.	_

48-1	8756-8760	Each	_
48-2	8761-8766	brain	_
48-3	8767-8773	volume	_
48-4	8774-8783	consisted	_
48-5	8784-8786	of	_
48-6	8787-8789	40	_
48-7	8790-8795	axial	_
48-8	8796-8802	slices	_
48-9	8803-8804	,	_
48-10	8805-8808	and	_
48-11	8809-8813	each	_
48-12	8814-8824	functional	_
48-13	8825-8828	run	_
48-14	8829-8838	contained	_
48-15	8839-8842	150	_
48-16	8843-8848	image	_
48-17	8849-8856	volumes	_
48-18	8857-8865	preceded	_
48-19	8866-8868	by	_
48-20	8869-8873	four	_
48-21	8874-8879	dummy	_
48-22	8880-8887	volumes	_
48-23	8888-8889	.	_

49-1	8890-8902	Participants	_
49-2	8903-8907	were	_
49-3	8908-8913	asked	_
49-4	8914-8916	to	_
49-5	8917-8921	stay	_
49-6	8922-8927	awake	_
49-7	8928-8929	,	_
49-8	8930-8933	not	_
49-9	8934-8936	to	_
49-10	8937-8942	focus	_
49-11	8943-8948	their	_
49-12	8949-8957	thoughts	_
49-13	8958-8960	on	_
49-14	8961-8969	anything	_
49-15	8970-8972	in	_
49-16	8973-8983	particular	_
49-17	8984-8985	,	_
49-18	8986-8989	and	_
49-19	8990-8992	to	_
49-20	8993-8997	keep	_
49-21	8998-9003	their	_
49-22	9004-9008	eyes	_
49-23	9009-9015	closed	_
49-24	9016-9022	during	_
49-25	9023-9029	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
49-26	9030-9038	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
49-27	9039-9040	.	_

50-1	9041-9047	RsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
50-2	9048-9052	data	_
50-3	9053-9066	preprocessing	_
50-4	9067-9070	was	_
50-5	9071-9080	performed	_
50-6	9081-9085	with	_
50-7	9086-9090	Data	_
50-8	9091-9101	Processing	_
50-9	9102-9111	Assistant	_
50-10	9112-9115	for	_
50-11	9116-9129	Resting‐State	_
50-12	9130-9134	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
50-13	9135-9143	Advanced	_
50-14	9144-9151	Edition	_
50-15	9152-9153	(	_
50-16	9154-9162	DPARSF‐A	_
50-17	9163-9164	)	_
50-18	9165-9172	version	_
50-19	9173-9176	2.1	_
50-20	9177-9188	software,31	_
50-21	9189-9190	,	_
50-22	9191-9193	32	_
50-23	9194-9199	which	_
50-24	9200-9202	is	_
50-25	9203-9204	a	_
50-26	9205-9211	matlab	_
50-27	9212-9213	(	_
50-28	9214-9223	MathWorks	_
50-29	9224-9225	,	_
50-30	9226-9232	Natick	_
50-31	9233-9234	,	_
50-32	9235-9237	MA	_
50-33	9238-9239	,	_
50-34	9240-9243	USA	_
50-35	9244-9245	)	_
50-36	9246-9253	toolbox	_
50-37	9254-9255	.	_

51-1	9256-9263	Imaging	_
51-2	9264-9268	data	_
51-3	9269-9273	were	_
51-4	9274-9282	adjusted	_
51-5	9283-9286	for	_
51-6	9287-9288	a	_
51-7	9289-9297	temporal	_
51-8	9298-9303	shift	_
51-9	9304-9306	in	_
51-10	9307-9318	acquisition	_
51-11	9319-9320	,	_
51-12	9321-9330	spatially	_
51-13	9331-9340	realigned	_
51-14	9341-9343	to	_
51-15	9344-9347	the	_
51-16	9348-9354	middle	_
51-17	9355-9360	slice	_
51-18	9361-9362	,	_
51-19	9363-9374	nonlinearly	_
51-20	9375-9385	normalized	_
51-21	9386-9388	to	_
51-22	9389-9392	the	_
51-23	9393-9396	EPI	_
51-24	9397-9400	MNI	_
51-25	9401-9409	template	_
51-26	9410-9411	(	_
51-27	9412-9421	resulting	_
51-28	9422-9424	in	_
51-29	9425-9427	an	_
51-30	9428-9437	isotropic	_
51-31	9438-9443	voxel	_
51-32	9444-9448	size	_
51-33	9449-9451	of	_
51-34	9452-9453	3	_
51-35	9454-9455	×	_
51-36	9456-9457	3	_
51-37	9458-9459	×	_
51-38	9460-9461	3	_
51-39	9462-9464	mm	_
51-40	9465-9466	)	_
51-41	9467-9468	,	_
51-42	9469-9477	smoothed	_
51-43	9478-9483	using	_
51-44	9484-9485	a	_
51-45	9486-9496	full‐width	_
51-46	9497-9499	at	_
51-47	9500-9512	half‐maximum	_
51-48	9513-9519	kernel	_
51-49	9520-9522	of	_
51-50	9523-9524	4	_
51-51	9525-9527	mm	_
51-52	9528-9529	,	_
51-53	9530-9533	and	_
51-54	9534-9542	bandpass	_
51-55	9543-9551	filtered	_
51-56	9552-9553	(	_
51-57	9554-9562	0.01–0.1	_
51-58	9563-9565	Hz	_
51-59	9566-9567	)	_
51-60	9568-9569	.	_

52-1	9570-9578	Nuisance	_
52-2	9579-9586	signals	_
52-3	9587-9591	from	_
52-4	9592-9595	the	_
52-5	9596-9607	head‐motion	_
52-6	9608-9612	time	_
52-7	9613-9619	series	_
52-8	9620-9629	estimated	_
52-9	9630-9632	by	_
52-10	9633-9636	the	_
52-11	9637-9644	Friston	_
52-12	9645-9657	24‐parameter	_
52-13	9658-9666	model,33	_
52-14	9667-9669	as	_
52-15	9670-9674	well	_
52-16	9675-9677	as	_
52-17	9678-9685	signals	_
52-18	9686-9690	from	_
52-19	9691-9696	white	_
52-20	9697-9703	matter	_
52-21	9704-9707	and	_
52-22	9708-9721	cerebrospinal	_
52-23	9722-9727	fluid	_
52-24	9728-9735	signals	_
52-25	9736-9737	,	_
52-26	9738-9742	were	_
52-27	9743-9752	regressed	_
52-28	9753-9756	out	_
52-29	9757-9759	of	_
52-30	9760-9764	each	_
52-31	9765-9770	voxel	_
52-32	9771-9773	's	_
52-33	9774-9778	time	_
52-34	9779-9785	course	_
52-35	9786-9787	.	_

53-1	9788-9796	Moreover	_
53-2	9797-9798	,	_
53-3	9799-9802	the	_
53-4	9803-9807	head	_
53-5	9808-9814	motion	_
53-6	9815-9824	scrubbing	_
53-7	9825-9835	regression	_
53-8	9836-9839	was	_
53-9	9840-9847	modeled	_
53-10	9848-9853	using	_
53-11	9854-9857	the	_
53-12	9858-9867	following	_
53-13	9868-9878	parameters	_
53-14	9879-9880	:	_
53-15	9881-9890	framewise	_
53-16	9891-9903	displacement	_
53-17	9904-9913	threshold	_
53-18	9914-9917	for	_
53-19	9918-9919	‘	_
53-20	9920-9923	bad	_
53-21	9924-9925	’	_
53-22	9926-9937	time‐points	_
53-23	9938-9939	,	_
53-24	9940-9943	0.5	_
53-25	9944-9945	;	_
53-26	9946-9955	scrubbing	_
53-27	9956-9967	time‐points	_
53-28	9968-9974	before	_
53-29	9975-9976	‘	_
53-30	9977-9980	bad	_
53-31	9981-9982	’	_
53-32	9983-9994	time‐points	_
53-33	9995-9996	,	_
53-34	9997-9998	1	_
53-35	9999-10000	;	_
53-36	10001-10004	and	_
53-37	10005-10014	scrubbing	_
53-38	10015-10026	time‐points	_
53-39	10027-10032	after	_
53-40	10033-10034	‘	_
53-41	10035-10038	bad	_
53-42	10039-10040	’	_
53-43	10041-10052	time‐points	_
53-44	10053-10054	,	_
53-45	10055-10059	2.34	_
53-46	10060-10067	Finally	_
53-47	10068-10069	,	_
53-48	10070-10073	the	_
53-49	10074-10078	time	_
53-50	10079-10085	course	_
53-51	10086-10090	data	_
53-52	10091-10095	were	_
53-53	10096-10105	processed	_
53-54	10106-10109	for	_
53-55	10110-10114	each	_
53-56	10115-10120	voxel	_
53-57	10121-10122	,	_
53-58	10123-10125	as	_
53-59	10126-10130	well	_
53-60	10131-10133	as	_
53-61	10134-10137	for	_
53-62	10138-10142	each	_
53-63	10143-10145	of	_
53-64	10146-10149	the	_
53-65	10150-10155	brain	_
53-66	10156-10163	regions	_
53-67	10164-10171	defined	_
53-68	10172-10174	by	_
53-69	10175-10178	the	_
53-70	10179-10193	Harvard–Oxford	_
53-71	10194-10199	atlas	_
53-72	10200-10211	distributed	_
53-73	10212-10216	with	_
53-74	10217-10220	FSL	_
53-75	10221-10222	(	_
53-76	10223-10227	http	_
53-77	10228-10229	:	_
53-78	10230-10255	//www.fmrib.ox.ac.uk/fsl/	_
53-79	10256-10257	)	_
53-80	10258-10259	,	_
53-81	10260-10262	by	_
53-82	10263-10272	averaging	_
53-83	10273-10277	over	_
53-84	10278-10284	voxels	_
53-85	10285-10291	within	_
53-86	10292-10296	each	_
53-87	10297-10303	region	_
53-88	10304-10305	.	_

54-1	10306-10319	Intraregional	_
54-2	10320-10331	correlation	_
54-3	10332-10344	coefficients	_
54-4	10345-10355	indicating	_
54-5	10356-10359	the	_
54-6	10360-10366	extent	_
54-7	10367-10369	of	_
54-8	10370-10383	synchronicity	_
54-9	10384-10388	were	_
54-10	10389-10399	calculated	_
54-11	10400-10407	between	_
54-12	10408-10413	every	_
54-13	10414-10418	pair	_
54-14	10419-10421	of	_
54-15	10422-10423	a	_
54-16	10424-10435	subcortical	_
54-17	10436-10442	region	_
54-18	10443-10446	and	_
54-19	10447-10448	a	_
54-20	10449-10454	voxel	_
54-21	10455-10456	,	_
54-22	10457-10460	and	_
54-23	10461-10473	connectivity	_
54-24	10474-10478	maps	_
54-25	10479-10483	were	_
54-26	10484-10491	created	_
54-27	10492-10493	.	_

55-1	10494-10505	Correlation	_
55-2	10506-10518	coefficients	_
55-3	10519-10531	representing	_
55-4	10532-10542	functional	_
55-5	10543-10555	connectivity	_
55-6	10556-10557	(	_
55-7	10558-10560	FC	_
55-8	10561-10562	)	_
55-9	10563-10567	were	_
55-10	10568-10577	converted	_
55-11	10578-10580	to	_
55-12	10581-10589	z‐scores	_
55-13	10590-10595	using	_
55-14	10596-10602	Fisher	_
55-15	10603-10605	's	_
55-16	10606-10620	transformation	_
55-17	10621-10622	.	_

56-1	10623-10634	Statistical	_
56-2	10635-10643	analysis	_
56-3	10644-10647	for	_
56-4	10648-10655	imaging	_
56-5	10656-10660	data	_
56-6	10661-10672	Statistical	_
56-7	10673-10681	analyses	_
56-8	10682-10686	were	_
56-9	10687-10696	performed	_
56-10	10697-10702	using	_
56-11	10703-10707	spss	_
56-12	10708-10711	for	_
56-13	10712-10719	Windows	_
56-14	10720-10727	Version	_
56-15	10728-10730	24	_
56-16	10731-10732	(	_
56-17	10733-10737	SPSS	_
56-18	10738-10743	Japan	_
56-19	10744-10748	Inc.	_
56-20	10749-10750	,	_
56-21	10751-10756	Tokyo	_
56-22	10757-10758	,	_
56-23	10759-10764	Japan	_
56-24	10765-10766	)	_
56-25	10767-10768	.	_

57-1	10769-10772	For	_
57-2	10773-10777	each	_
57-3	10778-10787	segmented	_
57-4	10788-10797	structure	_
57-5	10798-10799	,	_
57-6	10800-10806	except	_
57-7	10807-10810	for	_
57-8	10811-10814	the	_
57-9	10815-10818	ICV	_
57-10	10819-10820	,	_
57-11	10821-10822	a	_
57-12	10823-10828	total	_
57-13	10829-10831	of	_
57-14	10832-10835	798	_
57-15	10836-10844	subjects	_
57-16	10845-10846	(	_
57-17	10847-10850	633	_
57-18	10851-10859	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
57-19	10860-10861	,	_
57-20	10862-10865	111	_
57-21	10866-10874	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
57-22	10875-10879	with	_
57-23	10880-10892	deteriorated	_
57-24	10893-10895	IQ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
57-25	10896-10897	,	_
57-26	10898-10901	and	_
57-27	10902-10904	54	_
57-28	10905-10913	patients	_
57-29	10914-10918	with	_
57-30	10919-10928	preserved	_
57-31	10929-10931	IQ	_
57-32	10932-10933	)	_
57-33	10934-10938	were	_
57-34	10939-10947	compared	_
57-35	10948-10953	using	_
57-36	10954-10962	analysis	_
57-37	10963-10965	of	_
57-38	10966-10976	covariance	_
57-39	10977-10978	(	_
57-40	10979-10985	ancova	_
57-41	10986-10987	)	_
57-42	10988-10989	,	_
57-43	10990-10999	including	_
57-44	11000-11003	age	_
57-45	11004-11005	,	_
57-46	11006-11009	sex	_
57-47	11010-11011	,	_
57-48	11012-11016	type	_
57-49	11017-11019	of	_
57-50	11020-11023	MRI	_
57-51	11024-11031	scanner	_
57-52	11032-11033	,	_
57-53	11034-11037	and	_
57-54	11038-11041	ICV	_
57-55	11042-11044	as	_
57-56	11045-11055	covariates	_
57-57	11056-11057	.	_

58-1	11058-11061	The	_
58-2	11062-11065	ICV	_
58-3	11066-11069	was	_
58-4	11070-11078	analyzed	_
58-5	11079-11084	using	_
58-6	11085-11091	ancova	_
58-7	11092-11093	,	_
58-8	11094-11103	including	_
58-9	11104-11107	age	_
58-10	11108-11109	,	_
58-11	11110-11113	sex	_
58-12	11114-11115	,	_
58-13	11116-11119	and	_
58-14	11120-11124	type	_
58-15	11125-11127	of	_
58-16	11128-11131	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
58-17	11132-11139	scanner	_
58-18	11140-11142	as	_
58-19	11143-11153	covariates	_
58-20	11154-11155	.	_

59-1	11156-11163	Because	_
59-2	11164-11169	there	_
59-3	11170-11174	were	_
59-4	11175-11177	94	_
59-5	11178-11183	brain	_
59-6	11184-11191	regions	_
59-7	11192-11193	,	_
59-8	11194-11205	statistical	_
59-9	11206-11218	significance	_
59-10	11219-11222	was	_
59-11	11223-11230	defined	_
59-12	11231-11233	at	_
59-13	11234-11235	P	_
59-14	11236-11237	<	_
59-15	11238-11241	5.3	_
59-16	11242-11243	×	_
59-17	11244-11248	10−4	_
59-18	11249-11250	.	_

60-1	11251-11254	All	_
60-2	11255-11263	reported	_
60-3	11264-11272	P‐values	_
60-4	11273-11276	are	_
60-5	11277-11282	based	_
60-6	11283-11285	on	_
60-7	11286-11296	two‐tailed	_
60-8	11297-11302	tests	_
60-9	11303-11304	.	_

61-1	11305-11313	Post‐hoc	_
61-2	11314-11325	comparisons	_
61-3	11326-11330	were	_
61-4	11331-11340	performed	_
61-5	11341-11346	after	_
61-6	11347-11353	ancova	_
61-7	11354-11359	using	_
61-8	11360-11363	the	_
61-9	11364-11374	Bonferroni	_
61-10	11375-11385	correction	_
61-11	11386-11390	when	_
61-12	11391-11396	there	_
61-13	11397-11400	was	_
61-14	11401-11402	a	_
61-15	11403-11414	significant	_
61-16	11415-11425	difference	_
61-17	11426-11431	among	_
61-18	11432-11435	the	_
61-19	11436-11442	groups	_
61-20	11443-11444	.	_

62-1	11445-11456	Statistical	_
62-2	11457-11469	significance	_
62-3	11470-11473	was	_
62-4	11474-11481	defined	_
62-5	11482-11485	for	_
62-6	11486-11494	post‐hoc	_
62-7	11495-11506	comparisons	_
62-8	11507-11509	at	_
62-9	11510-11511	P	_
62-10	11512-11513	<	_
62-11	11514-11518	0.05	_
62-12	11519-11520	.	_

63-1	11521-11526	Cohen	_
63-2	11527-11529	's	_
63-3	11530-11531	d	_
63-4	11532-11538	effect	_
63-5	11539-11544	sizes	_
63-6	11545-11549	were	_
63-7	11550-11560	calculated	_
63-8	11561-11568	between	_
63-9	11569-11572	the	_
63-10	11573-11579	groups	_
63-11	11580-11581	.	_

64-1	11582-11583	A	_
64-2	11584-11589	total	_
64-3	11590-11592	of	_
64-4	11593-11596	294	_
64-5	11597-11605	subjects	_
64-6	11606-11607	(	_
64-7	11608-11611	234	_
64-8	11612-11620	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
64-9	11621-11622	,	_
64-10	11623-11625	40	_
64-11	11626-11634	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
64-12	11635-11639	with	_
64-13	11640-11652	deteriorated	_
64-14	11653-11655	IQ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
64-15	11656-11657	,	_
64-16	11658-11661	and	_
64-17	11662-11664	20	_
64-18	11665-11673	patients	_
64-19	11674-11678	with	_
64-20	11679-11688	preserved	_
64-21	11689-11691	IQ	_
64-22	11692-11693	)	_
64-23	11694-11698	were	_
64-24	11699-11707	analyzed	_
64-25	11708-11711	for	_
64-26	11712-11717	brain	_
64-27	11718-11730	connectivity	_
64-28	11731-11732	.	_

65-1	11733-11736	The	_
65-2	11737-11749	second‐level	_
65-3	11750-11758	analyses	_
65-4	11759-11761	of	_
65-5	11762-11772	seed‐based	_
65-6	11773-11775	FC	_
65-7	11776-11780	maps	_
65-8	11781-11785	were	_
65-9	11786-11795	performed	_
65-10	11796-11798	in	_
65-11	11799-11804	spm12	_
65-12	11805-11806	(	_
65-13	11807-11815	Wellcome	_
65-14	11816-11826	Department	_
65-15	11827-11829	of	_
65-16	11830-11839	Cognitive	_
65-17	11840-11849	Neurology	_
65-18	11850-11851	,	_
65-19	11852-11858	London	_
65-20	11859-11860	,	_
65-21	11861-11863	UK	_
65-22	11864-11865	)	_
65-23	11866-11873	running	_
65-24	11874-11876	on	_
65-25	11877-11883	MATLAB	_
65-26	11884-11890	R2014b	_
65-27	11891-11892	.	_

66-1	11893-11895	We	_
66-2	11896-11904	compared	_
66-3	11905-11915	functional	_
66-4	11916-11928	connectivity	_
66-5	11929-11933	maps	_
66-6	11934-11940	seeded	_
66-7	11941-11943	in	_
66-8	11944-11947	the	_
66-9	11948-11957	bilateral	_
66-10	11958-11966	thalamus	_
66-11	11967-11968	,	_
66-12	11969-11978	accumbens	_
66-13	11979-11980	,	_
66-14	11981-11989	amygdala	_
66-15	11990-11991	,	_
66-16	11992-11999	caudate	_
66-17	12000-12007	nucleus	_
66-18	12008-12009	,	_
66-19	12010-12021	hippocampus	_
66-20	12022-12023	,	_
66-21	12024-12032	pallidum	_
66-22	12033-12034	,	_
66-23	12035-12038	and	_
66-24	12039-12046	putamen	_
66-25	12047-12054	between	_
66-26	12055-12058	the	_
66-27	12059-12071	deteriorated	_
66-28	12072-12077	group	_
66-29	12078-12081	and	_
66-30	12082-12089	control	_
66-31	12090-12095	group	_
66-32	12096-12097	,	_
66-33	12098-12101	the	_
66-34	12102-12111	preserved	_
66-35	12112-12117	group	_
66-36	12118-12121	and	_
66-37	12122-12129	control	_
66-38	12130-12135	group	_
66-39	12136-12137	,	_
66-40	12138-12141	and	_
66-41	12142-12145	the	_
66-42	12146-12158	deteriorated	_
66-43	12159-12164	group	_
66-44	12165-12168	and	_
66-45	12169-12178	preserved	_
66-46	12179-12184	group	_
66-47	12185-12196	controlling	_
66-48	12197-12200	for	_
66-49	12201-12204	age	_
66-50	12205-12208	and	_
66-51	12209-12212	sex	_
66-52	12213-12214	.	_

67-1	12215-12218	For	_
67-2	12219-12222	the	_
67-3	12223-12231	analysis	_
67-4	12232-12234	of	_
67-5	12235-12237	FC	_
67-6	12238-12242	maps	_
67-7	12243-12244	,	_
67-8	12245-12248	the	_
67-9	12249-12260	statistical	_
67-10	12261-12270	threshold	_
67-11	12271-12274	was	_
67-12	12275-12278	set	_
67-13	12279-12281	at	_
67-14	12282-12284	an	_
67-15	12285-12296	uncorrected	_
67-16	12297-12298	P	_
67-17	12299-12300	<	_
67-18	12301-12306	0.001	_
67-19	12307-12309	at	_
67-20	12310-12313	the	_
67-21	12314-12319	voxel	_
67-22	12320-12325	level	_
67-23	12326-12329	and	_
67-24	12330-12331	a	_
67-25	12332-12359	family‐wise‐error‐corrected	_
67-26	12360-12361	P	_
67-27	12362-12363	<	_
67-28	12364-12368	0.05	_
67-29	12369-12371	at	_
67-30	12372-12375	the	_
67-31	12376-12383	cluster	_
67-32	12384-12389	level	_
67-33	12390-12391	.	_

